<DOC>
	<DOCNO>NCT00002819</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy radiation therapy use kill tumor cell . It yet know whether chemotherapy alone effective chemotherapy plus peripheral stem cell transplantation ovarian epithelial cancer . PURPOSE : Randomized phase III trial compare effectiveness paclitaxel carboplatin carboplatin , mitoxantrone , cyclophosphamide follow peripheral stem cell transplantation treat patient persistent stage III stage IV ovarian epithelial cancer .</brief_summary>
	<brief_title>Chemotherapy With Without Peripheral Stem Cell Transplantation Treating Patients With Persistent Ovarian Epithelial Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare progression-free overall survival patient drug-sensitive , low-volume ovarian cancer persistent follow standard therapy treat salvage therapy comprise standard-dose paclitaxel carboplatin v high-dose carboplatin , mitoxantrone , cyclophosphamide follow bone marrow reconstitution . II . Compare toxic effect two salvage regimen . III . Compare select health-related aspect quality life patient . OUTLINE : This randomize , multicenter study . Patients stratify participate center disease state reassessment laparotomy . Patients randomize one two treatment arm . Arm I : Patients receive paclitaxel IV 3 hour day 1 carboplatin IV continuously day 1-5 every 3 week total 6 course . Arm II : Patients receive cyclophosphamide IV 1 hour mitoxantrone IV 15 minute day -8 , -6 , -4 , carboplatin IV continuously day -8 -4 , follow rescue autologous bone marrow peripheral blood stem cell day 0 . Quality life assess baseline , 3 9 week start treatment , every 3 month additional 5 assessment regardless disease progression . PROJECTED ACCRUAL : A total 275 patient accrue approximately 60 month .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage III IV ovarian epithelial carcinoma include follow cellular diagnosis : Serous adenocarcinoma Mucinous adenocarcinoma Endometrioid adenocarcinoma Clear cell adenocarcinoma Undifferentiated carcinoma Mixed epithelial carcinoma Transitional cell carcinoma Malignant Brenner 's Tumor Stage III ( optimal suboptimal ) must surgically reassess OR Stage III ( suboptimal ) stage IV clinically reassess induction chemotherapy For stage III surgical reassessment : No 12 week end chemotherapy reassessment surgery AND No 6 week reassessment surgery randomization Patients treat protocol GOG158 eligible At least partial response chemotherapy define : Microscopic disease document reassessment surgery patient optimally debulked ( disease great 1 cm ) primary surgery Suboptimally debulked disease ( great 1 cm ) primary surgery 1 following : Negative reassessment laparotomy Only microscopic disease reassessment surgery Gross residual disease great 1 cm reassessment surgery prior debulking Clinical complete response induction chemotherapy include : suboptimal disease Stage III IV AND either abnormal CT elevate CA125 prior induction chemotherapy within normal limit follow induction chemotherapy PATIENT CHARACTERISTICS : Age : Under 66 Performance status : GOG 0 1 Hematopoietic : Absolute granulocyte count least 1,000/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL AST great 3 time normal Renal : Creatinine clearance least 60 mL/min Cardiovascular : Left ventricular ejection fraction least 45 % MUGA No congestive heart failure Pulmonary : FEV1 FVC least 60 % Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior malignancy past 5 year except adequately treat nonmelanomatous skin cancer , carcinoma situ cervix , cancer whose prior treatment contraindicate study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 4 6 prior platinumbased combination chemotherapy course ( i.e. , cisplatin carboplatin ) require Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics Other : No prior anthracyclines</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>ovarian undifferentiated adenocarcinoma</keyword>
	<keyword>ovarian mixed epithelial carcinoma</keyword>
	<keyword>ovarian serous cystadenocarcinoma</keyword>
	<keyword>ovarian mucinous cystadenocarcinoma</keyword>
	<keyword>ovarian endometrioid adenocarcinoma</keyword>
	<keyword>ovarian clear cell cystadenocarcinoma</keyword>
	<keyword>Brenner tumor</keyword>
</DOC>